All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Join our

Live Symposium

How to sequence BCMA-directed therapies in early relapsed/ refractory multiple myeloma

At the ESH 7th Translational Research Conference:

Multiple Myeloma

with Martin Kaiser, Mohamad Mohty, and Rakesh Popat

Saturday, October 5, 2024 | 09:10-10:10 CEST

Register now

This independent educational activity is funded by GSK. All content is developed independently by the faculty. The funders are allowed no influence on the content of this activity.

  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-01-05T11:21:14.000Z

PERSEUS: Primary efficacy and safety results

Jan 5, 2024
Share:
Learning objective: After reading this article, learners will be able to cite key efficacy and safety data from the phase III PERSEUS trial.

Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.

Bortezomib, lenalidomide, and dexamethasone (VRd) induction followed by autologous stem cell transplantation, VRd consolidation, and lenalidomide maintenance is currently considered the standard of care for patients with transplant-eligible newly diagnosed multiple myeloma (NDMM). However, new treatment directions are needed to further increase the depth of response and long-term disease control.

Daratumumab, a CD38 monoclonal antibody, is currently approved for use in several treatment regimens aimed at both transplant-eligible and non-transplant-eligible NDMM. Recently, the phase II GRIFFIN study (NCT02874742) investigated the addition of daratumumab to VRd induction and consolidation with lenalidomide maintenance for transplant-eligible NDMM. Results showed a greater depth of response and longer progression-free survival (PFS) compared with VRd and lenalidomide alone.

The randomized phase III PERSEUS trial (NCT03710603) subsequently investigated daratumumab in combination with VRd and lenalidomide compared with VRd and lenalidomide alone in patients with transplant-eligible NDMM. The primary results of the study were recently presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition by Sonneveld. We summarize the key points below.

Study design1

  • Open label, multicenter, randomized trial
  • Across 14 countries and 115 sites
  • January 19, 2019 to January 3, 2020
  • Patient eligibility criteria:
    • Age 18–70 years
    • Confirmed diagnosis of NDMM
    • Eligible for high-dose therapy and autologous stem cell transplantation
    • Eastern Cooperative Oncology Group performance-scale score 0–2
  • The full study design is shown in Figure 1

Figure 1. PERSEUS study design* 

d, dexamethasone; DARA, daratumumab; D-VRd, daratumumab + bortezomib + lenalidomide + dexamethasone; MRD, measurable residual disease; PD, progressive disease; PO, oral; R, lenalidomide; SC, subcutaneous; V, bortezomib; VRd, bortezomib + lenalidomide + dexamethasone.
*Adapted from Sonneveld.1

  • The primary study endpoint was PFS
  • The key secondary study endpoints were complete response (CR) or better, overall survival, and negative measurable residual disease (MRD) with CR or better

Results1

  • In total, 709 patients were enrolled and randomized 1:1.
    • There were 355 patients in the daratumumab + VRd (D-VRd) group
    • The VRd group included 354 patients
  • Patient characteristics at baseline were balanced between the two treatment groups (Table 1).
  • Overall, 89.7% of patients treated with D-VRd underwent transplantation compared with 87% of patients treated with VRd.

Table 1. Baseline patient characteristics*

Characteristic, % (unless otherwise stated)

D-VRd
(n = 355)

VRd
(n = 354)

Median age, years

61.0

59.0

Male

59.4

57.9

ECOG PS score

              0

62.3

65.0

              1

32.1

30.5

              2

5.4

4.5

              3

0.3

0

ISS stage

              I

52.4

50.4

              II

32.1

35.4

              III

15.5

14.2

Cytogenetic profile

              Standard risk

74.4

75.1

              Intermediate risk

4.2

2.8

              High risk

21.4

22.0

MM diagnosis

              CRAB criteria only

35.3

32.1

              Biomarkers of malignancy only

14.7

18.5

              CRAB criteria and biomarkers of               malignancy

50.0

49.4

CRAB, calcium renal anemia bone; D-VRd, daratumumab + bortezomib + lenalidomide + dexamethasone;
ECOG PS, European Cooperative Oncology Group performance scale; ISS, International Staging System; MM,
multiple myeloma; VRd, bortezomib + lenalidomide + dexamethasone.
*Adapted from Sonneveld.1

Efficacy

  • The median follow-up was 47.5 months
  • Both PFS and achieving a CR or better were significantly higher in patients treated with D-VRd vs VRd (Figure 2)

Figure 2. PFS and rates of a CR or better in patients treated with D-VRd vs VRd* 

CR, complete response; D-VRd, daratumumab + bortezomib + lenalidomide + dexamethasone; PFS, progression-free survival; VRd, bortezomib + lenalidomide + dexamethasone.
*Adapted from Sonneveld.1

  • Patients treated with D-VRd experienced a 58% reduction in the risk of progression/death compared with patients treated with VRd (hazard ratio, 0.42).
  • The rates of overall negative MRD at a sensitivity of 10−5, 10−6, and sustained negative MRD at 12 months are shown in Figure 3.
  • In total, 64% of patients discontinued daratumumab maintenance after achieving sustained negative MRD.

Figure 3. Rates of overall negative MRD at a sensitivity of 10−5, 10−6, and sustained negative MRD at 12 months* 

D-VRd, daratumumab + bortezomib + lenalidomide + dexamethasone; MRD, measurable residual disease; VRd, bortezomib + lenalidomide + dexamethasone.
*Adapted from Sonneveld.1

 Safety

  • The most common Grade 3–4 adverse events (AEs) experienced by ≥10% of patients in either treatment group are shown in Figure 4.
  • Overall, 9.1% of patients in the D-VRd group experienced an adverse event that led to treatment discontinuation vs 22.5% of patients in the VRd group

Figure 4. Most common Grade 3–4 AEs experienced by ≥10% of patients in either treatment group* 

AE, adverse event; D-VRd, daratumumab + bortezomib + lenalidomide + dexamethasone; VRd, bortezomib + lenalidomide + dexamethasone.
*Adapted from Sonneveld.1

 Conclusion

These results, in combination with those of the GRIFFIN and CASSIOPEIA (NCT02541383) trials highlight a significant and meaningful clinical benefit in depth of response, PFS, and MRD negativity with D-VRd together with daratumumab and lenalidomide maintenance. The risk-benefit profile was also favorable. Together, these results demonstrate the potential of this regimen as a standard-of-care treatment for transplant-eligible patients with NDMM.

  1. Sonneveld P. Phase 3 randomized study of daratumumab (DARA) + bortezomib, lenalidomide, and dexamethasone (VRd) vs VRd alone in patients (Pts) with newly diagnosed multiple myeloma (NDMM) who are eligible for autologous stem cell transplantation (ASCT): primary results of the Perseus trial. Oral abstract #1. 65th American Society of Hematology Annual Meeting and Exposition Dec 12, 2023; San Diego, US.

Your opinion matters

HCPs, what is your preferred format for educational content on the Multiple Myeloma Hub?
39 votes - 30 days left ...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox